Sale on Ophthalmic Equipment - Starting from 16 November!
Science Corporation has raised $400 million in a Series D round to expand its Prima retinal implant across Europe and prepare for a US launch.
Science Corporation has raised $400 million in a Series D round to expand its Prima retinal implant across Europe. The company is also preparing to enter the US market. The new money lifts the total raised by Science Corporation since its start in 2021 to over $900 million.
Investors in the round included 885 Capital, Khosla Ventures, PLC Neurotech, Tenet Healthcare, the Ackman Oxman Institute and Y Combinator, among others.
Prima is a brain computer interface made to restore form vision. It aims to help people blinded by some advanced forms of macular degeneration. These users could read letters, numbers and words, the company says. The Prima retinal implant won a European CE mark in July 2026.
The system pairs a small implant with special glasses. Together they are meant to take over the job of damaged photoreceptor cells, which normally sense light. A camera on the front of the glasses and a projector facing inward send light patterns to the implant. The implant has 378 pixels that respond to light. The design is still being tested, so results in daily use are not yet clear.
Science plans to scale up manufacturing, clinical research and operations. It will also advance its biohybrid programme, which combines engineered neurons with biological brain circuitry.
In the US, Science is getting ready for a launch. It is seeking clearance from the US Food and Drug Administration through a humanitarian device exemption.
The Prima retinal implant is under evaluation for geographic atrophy caused by dry age related macular degeneration. Researchers are also assessing whether the platform could help with other inherited retinal conditions, such as retinitis pigmentosa and Stargardt disease.
Earlier this year, Science raised $230 million to support commercial activity for Prima.
The Prima retinal implant is moving from trials towards wider use in Europe, and the company says a US launch is next. Medigear.uk helps clinical buyers compare verified suppliers. The company's plans, device claims and US clearance goals are its own, and none is guaranteed. UK buyers should check UK approval and availability.
Source: Medical Device Network
Tell us the model and destination — our sourcing team will respond within one business day.

The Zimmer Monogram robot is now with US regulators. Zimmer Biomet has filed a 510(k) submission for…

The Abbott Encantor trial has begun. Abbott said on Thursday that it has started the VOYAGER CE clin…

Johnson & Johnson (J&J) said on Thursday that a Houston hospital will be the first to instal…
Approvals, trials, recalls and market moves — the essentials for procurement and clinical teams.